GlassScriptPhysician profile
Tiffany J Spaulding
NPI 1679704753
$2,465.81
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $528 · 2020: $380 · 2021: $563 · 2022: $502 · 2023: $367 · 2024: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.40 | 2021-2024 | Vraylar, Ubrelvy |
| Janssen Pharmaceuticals, INC | $242.58 | 2019-2022 | |
| Amgen INC. | $178.75 | 2019-2023 | Evenity, Prolia |
| Astellas Pharma US INC | $143.70 | 2019-2024 | Veozah |
| Allergan, INC. | $135.83 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $132.27 | 2019-2023 | Breztri |
| Otsuka America Pharmaceutical, INC. | $128.13 | 2019-2023 | Rexulti |
| Lilly USA, LLC | $112.99 | 2019-2023 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $110.53 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $107.05 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $93.64 | 2019-2021 | |
| Pfizer INC. | $70.60 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.74 | 2019-2023 | Trintellix |
| Novo Nordisk INC | $51.38 | 2020-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $41.33 | 2023-2024 | Auvelity |
| Boston Scientific Corporation | $40.82 | 2021-2023 | |
| Genentech USA, INC. | $39.15 | 2020-2021 | |
| Amarin Pharma, INC. | $32.99 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.41 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.75 | 2020-2021 | |
| Ucb, INC. | $22.59 | 2023 | Briviact |
| Biogen, INC. | $19.36 | 2022 | |
| Hologic Sales and Service, LLC | $17.70 | 2021 | |
| Merz North America, INC. | $17.54 | 2023 | Xeomin |
| Edwards Lifesciences Corporation | $17.34 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Horizon Therapeutics Plc | $14.75 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.70 | 2020 | |
| Mayne Pharma Commercial LLC | $13.74 | 2023 | |
| Novartis Pharmaceuticals Corporation | $13.13 | 2019 | |
| Neurelis, INC. | $13.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Spaulding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.